StatementBusinessSegments [Axis] Plasma Collection Centers Corporate Statement, Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Income Statement Location [Axis] Research and development Plasma centers Selling, general and administrative Debt Instrument [Axis] Oxford Loan Cost of goods sold Finite-Lived Intangible Assets by Major Class [Axis] Trademark and other intangible rights related to Nabi-HB Right to intermediates Customer contract Property, Plant and Equipment, Type [Axis] Manufacturing and laboratory equipment Office equipment and computer software Furniture and fixtures Leasehold improvements Land Buildings ADMA BioManufacturing Antidilutive Securities [Axis] Stock Options Warrants Construction in process Non-Voting Common Stock Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity's Reporting Status Current? Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets Cash and cash equivalents Accounts receivable, net Inventories Prepaid expenses and other current assets Total current assets Property and equipment, net Intangible assets, net Goodwill Assets to be transferred under purchase agreement Restricted cash Deposits and other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable Accrued expenses and other current liabilities Current portion of deferred revenue Current portion of lease obligations Total current liabilities Notes payable, net of discount End of term liability, notes payable Deferred revenue, net of current portion Note payable - related party, net of discount Obligation to transfer assets under purchase agreement Lease obligations, net of current portion Other non-current liabilities TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding Common Stock - voting, $0.0001 par value, 75,000,000 shares authorized, 46,353,068 shares issued and outstanding Additional Paid-In Capital Accumulated Deficit TOTAL STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Stockholders Equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value Common stock, shares authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] REVENUES: Product revenue License and other revenue Total Revenues OPERATING EXPENSES Cost of product revenue (exclusive of amortization expense shown below) Research and development Plasma center operating expenses Amortization of intangibles Selling, general and administrative TOTAL OPERATING EXPENSES LOSS FROM OPERATIONS OTHER INCOME (EXPENSE): Interest and other income Interest expense Loss on extinguishment of debt Gain on transfer of plasma center assets Other (expense) income Other income (expense), net NET LOSS BASIC AND DILUTED LOSS PER COMMON SHARE WEIGHTED AVERAGE SHARES OUTSTANDING, Basic and Diluted Statement [Table] Statement [Line Items] Equity Components [Axis] Beginning balance, shares Beginning balance, amount Stock-based compensation Stock options exercised Warrants issued in connection with note payable Net loss Ending balance, shares Ending balance, amount Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Loss on disposal of fixed assets Stock-based compensation Gain on transfer of plasma assets Amortization of debt discount Loss on extinguishment of debt Amortization of license revenue Changes in operating assets and liabilities, net of acquisition: Accounts receivable Inventories Prepaid expenses and other current assets Deposits and other assets Accounts payable Accrued expenses Other current and non-current liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment Net cash provided by (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Principal payments on note payable Payment of end of term fee Payment of debt refinancing fees Proceeds from issuance of note payable Payment of debt issuance costs Payments on capital lease obligations Payments of leasehold improvement loan Net cash provided by (used in) financing activities Net (decrease) increase in cash and cash equivalents Cash and cash equivalents, including restricted cash - beginning of period Cash and cash equivalents, including restricted cash - end of period Organization, Consolidation and Presentation of Financial Statements [Abstract] 1. ORGANIZATION AND BUSINESS Accounting Policies [Abstract] 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Inventory Disclosure [Abstract] 3. INVENTORIES Goodwill and Intangible Assets Disclosure [Abstract] 4. INTANGIBLE ASSETS Property, Plant and Equipment [Abstract] 5. PROPERTY AND EQUIPMENT Debt Disclosure [Abstract] 6. DEBT Stockholders' Equity Attributable to Parent [Abstract] 7. STOCKHOLDERS' EQUITY Related Party Transactions [Abstract] 8. RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] 9. COMMITMENT AND CONTINGENCIES Segment Reporting [Abstract] 10. SEGMENTS Transfer Of Plasma Center Assets 11. TRANSFER OF PLASMA CENTER ASSETS Leases [Abstract] 12. LEASE OBLIGATIONS Supplemental Cash Flow Information [Abstract] 13. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Subsequent Events [Abstract] 14. SUBSEQUENT EVENTS Basis of presentation Use of estimates Fair value of financial instruments Accounts receivable Inventories Goodwill Impairment of long-lived assets Revenue recognition Cost of product revenue Loss per common share Stock-based compensation Income Taxes Recent Accounting Pronouncements Schedule of dilutive securities Schedule of inventory Schedule of intangible assets Intangible asset future aggregate amortization expense Schedule of property and equipment Summary of notes payable Summary of related party notes payable Schedule of assumptions Schedule of stock option activity Stock-based compensation expense Schedule of related party transactions Summarized segment financial information Schedule of future minimum lease payments Schedule of supplemental cash flow information Accumulated deficit Potentially dilutive securities Raw materials Work-in-progress Finished goods Total inventories Cost Accumulated Amortization Net Remainder of 2019 2020 2021 2022 2023 Property, plant and equipment, gross Less: accumulated depreciation and amortization Property, plant and equipment, net Depreciation expense Notes payable Less: Debt discount Senior notes payable Related party note payable to Biotest Debt discount Note payable - related party Expected term Expected term, minimum Expected term, maximum Volatility Volatility, minimum Volatility, maximum Dividend yield Risk-free interest rate Risk-free interest rate, minimum Risk-free interest rate, maximum Shares Outstanding at beginning of period Forfeited Expired Granted Exercised Outstanding at end of period Options exercisable Weighted Average Exercise Price Outstanding at beginning of period Forfeited Expired Granted Exercised Outstanding at end of period Options exercisable Total stock-based compensation expense Unrecognized compensation expense Unrecognized compensation expense recognition period Sale and purchase of plasma Product revenue Purchases License revenue Interest expense Accounts receivable Prepaid expenses and other current assets Accounts payable Accrued expenses Note payable, net of discount Accrued interest Deferred revenue Segments [Axis] Revenues Cost of product revenue (Loss) income from operations Interest and other (expense) income, net Net (loss) income Purchase of property and equipment Depreciation and amortization expense Total assets Remainder of 2019 2020 2021 2022 2023 Thereafter Total payments Less: imputed interest Total SUPPLEMENTAL INFORMATION: Cash paid for interest Noncash Financing and Inesting Activities: Equipment acquired reflected in accounts payable and accrued liabilities Custom Element. Custom Element. Assets, Current Liabilities, Current Liabilities Additional Paid in Capital Stockholders' Equity Attributable to Parent Liabilities and Equity Research and Development Expense General and Administrative Expense Operating Expenses Interest Expense Nonoperating Income (Expense) Shares, Issued Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Increase (Decrease) in Other Operating Assets Increase (Decrease) in Accounts Payable Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Payments for Other Fees PaymentsOfDebtRefinancingFees Payments of Debt Issuance Costs Repayments of Debt and Capital Lease Obligations Repayments of Other Debt Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Cash Inventory, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Debt Instrument, Unamortized Discount Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Revenue from Related Parties Accounts Receivable, Related Parties PrepaidExpenseAndOtherAssetsRelatedParties Accounts Payable, Related Parties Accrued Liabilities, Fair Value Disclosure Operating Leases, Future Minimum Payments, Remainder of Fiscal Year Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments Due InterestPortionOfMinimumLeasePayments Operating Lease, Liability